|
|
 |
|
Viewing report
|
|
|
|
U.S. Hepatitis C Market
Frost & Sullivan, Oct 2011, Pages: 75
HCV is an infectious disease that leads to inflammation of the liver. Chronic infection can lead to fibrosis (scarring of the liver) and cirrhosis (advanced
scarring). The virus is spread by blood-to-blood contact. The SOC for treating hepatitis C is peginterferon and ribavirin. This research service covers the HCV market from 2008 to 2016, in the United States, with 2010 as the base year. Market products and products that are currently in their development stages are also analyzed in this research service.
The market is segmented into the following sections by drug classes:
- SOC: Peginterferon alfa and ribavirin
- Protease inhibitor
- Nucleotide (nuc) polymerase inhibitor
- Non-nucleotide polymerase inhibitor
- Nonstructural protein 5A (NS5A)
- Other
The units are chronic HCV infected patients.
Revenue were derived from the number of patients and price assumptions.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
